One of the best-studied diets for cardiovascular health is the Mediterranean diet. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Research
29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
There is evidence from a population-based study of an inverse relationship between monounsaturated fatty acids (MUFA) energy intake and age-related cognitive decline (ARCD), while high polyunsaturated fatty acids (PUFA) intake was positively associated with cognitive impairment in elderly subjects. 2 key findings →
Design: longitudinal study Participants: 704 Evidence: high
Full summary, score breakdown and related studies → Original source
Recent randomized control trials and meta-analyses of experimental studies indicate positive effects of non-pharmacological cognitive training on the cognitive function of healthy older adults. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The recent relevant evidence of the effects of the Mediterranean diet (MedDiet) and lifestyle on health (2015 and first months of 2016). 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
MIND diet is associated with better cognitive functioning independently of common brain pathology, suggesting that the MIND diet may contribute to cognitive resilience in the elderly. 4 key findings →
Design: longitudinal study Participants: 569 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Benefits of a Mediterranean diet for cognition have been suggested, but epidemiologic studies have been relatively small and of limited duration. 2 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
A number of health and lifestyle factors are thought to contribute to cognitive decline associated with age but cannot be easily modified by the individual patient. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
A higher adherence to the MedDiet might be associated with better cognitive function. 2 key findings →
Design: prospective cohort Participants: 823 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Behavioral prevention strategies can help maintain high levels of cognition and functional integrity, and can reduce the social, medical, and economic burden associated with cognitive aging and age-associated neurodegenerative diseases. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
The study aims to assess the efficacy of the Big Brain Academy (BBA), a computerized cognitive training program (CT) based on video games, compared to the Integrated Psychostimulation Program (IPP), a classical CT tool for patients with Alzheimer's disease (AD). 3 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Higher adherence to a Mediterranean-type diet was associated with decreased cognitive decline, although the Mediterranean diet (MeDi) combines several foods, micronutrients, and macronutrients already separately proposed as potential protective factors against dementia and predementia syndromes. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ⩾2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1-3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Chronic low serum 25-hydroxyvitamin D (25OHD) concentrations are common in adults and are associated with numerous non-skeletal diseases. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Forty-two case-control, cohort, and randomized trials were identified and included in the review. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Without validated cutoff scores, it is impossible to employ tests in a standardized fashion in front-line clinical settings. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Animal models point towards a key role of brain-derived neurotrophic factor (BDNF), insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in mediating exercise-induced structural and functional changes in the hippocampus. 2 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
Global concern on the potential impact of dementia is mounting. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
64/100
Social activity is associated with a decreased risk of incident disability in activities of daily living, mobility, and instrumental activities of daily living, among community-dwelling older adults. 4 key findings →
Design: cohort study Participants: 954 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Coffee is the leading worldwide beverage after water and its trade exceeds US $10 billion worldwide. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Hearing aids may have a mitigating effect on trajectories of cognitive decline in later life. 2 key findings →
Design: cohort study Participants: 2,040 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Motor inactivity is typical in the later stages of Alzheimer's disease although there is evidence that physical exercise can reduce depression and enhance performance of daily activities. 2 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
In the SoUth Korean study to PrEvent cognitive impaiRment and protect BRAIN health through lifestyle intervention in at-risk elderly people (SUPERBRAIN), we evaluated the impact of multidomain lifestyle intervention on regional homogeneity (ReHo) in resting-state functional brain magnetic resonance imaging (MRI) data. 2 key findings →
Design: longitudinal study Participants: 56 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Both objective and perceived social isolations were associated with future cognitive decline and increase risk of Alzheimer's disease (AD). 5 key findings →
Design: longitudinal study Participants: 23 Evidence: moderate
Full summary, score breakdown and related studies → Original source
53.0% of the participants were in the group of possible mild cognitive impairment (MCI). 5 key findings →
Design: cross-sectional Participants: 117 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Insomnia in elderly people has traditionally been regarded as inevitable and trivial. 2 key findings →
Design: longitudinal study Participants: 705 Evidence: moderate
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,962 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Role of Mediterranean diet in the prevention of cognitive decline: Biological mechanisms behind longevity promotion
- Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging
- Genetically decreased vitamin D and risk of Alzheimer disease
- Attitudes and views on healthy lifestyle interventions for the prevention of dementia and cardiovascular disease among older people with low socioeconomic status: a qualitative study in the Netherlands
- Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications
- Computerised cognitive training for preventing dementia in people with mild cognitive impairment
- Diet and Prevention of Cardiovascular Disease and Cancer
- Effect of a PROtein-enriched MEDiterranean diet and EXercise (PROMED-EX) on nutritional status and cognitive performance in older adults at risk of undernutrition and cognitive decline: the PROMED-EX randomized controlled trial
- Effect of Multidomain Intervention, Omega-3 Polyunsaturated Fatty Acids Supplementation or their Combinaison on Cognitive Function in Non-Demented Older Adults According to Frail Status: Results from the MAPT Study
- Self-applied single-channel mastoid ExG for fully automated detection of REM sleep behaviour disorder
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →